Smallpox Siege of Boston 1775-1776
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with...
- The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of...
- The SELECT trial focused on adults with obesity (BMI of 30 or higher) *and* established cardiovascular disease, such as a prior heart attack or stroke.This is a critical...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (ozempic). The study, involving over 17,600 participants, showed a statistically significant, though relatively small, increase in these events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and data Breakdown
The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of those receiving semaglutide versus 5.8% in the placebo group – a hazard ratio of 1.13. While this difference is statistically significant, itS crucial to understand the absolute risk increase. Specifically, this translates to approximately 1 additional cardiovascular event for every 98 people treated with semaglutide over the study period.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Cardiovascular Death | 1.5 | 1.2 | 1.26 |
| Nonfatal Myocardial infarction | 3.7 | 3.2 | 1.16 |
| Nonfatal Stroke | 1.9 | 1.5 | 1.27 |
| Composite Outcome (CV Death, MI, Stroke) | 6.5 | 5.8 | 1.13 |
Who is Affected? Understanding the Patient Profile
The SELECT trial focused on adults with obesity (BMI of 30 or higher) *and* established cardiovascular disease, such as a prior heart attack or stroke.This is a critical distinction. The findings do *not* necessarily apply to individuals using semaglutide for weight loss who do not have pre-existing cardiovascular conditions. Though, it raises critically important questions about the long-term cardiovascular effects of these medications in a broader population.
Furthermore, the study population was predominantly White (84.6%),limiting the generalizability of the findings to other racial and ethnic groups. Additional research is needed to determine if the observed risk varies across different populations.
What Dose This Mean? Implications for Patients and Physicians
These results necessitate a more cautious approach to prescribing semaglutide, particularly for patients with established cardiovascular disease. A thorough risk-benefit assessment is crucial, considering individual patient factors and choice treatment options. It’s vital to emphasize that the absolute risk increase is relatively small, but it’s not zero, and the long-term effects remain unknown.
The findings also highlight the importance of ongoing monitoring for cardiovascular events in patients taking semaglutide, even those without a prior history of heart disease. This includes regular check-ups, blood pressure monitoring, and awareness of potential symptoms like chest pain or shortness of breath.